Kristin E Karlsson
Cited by
Cited by
Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis
MLE Andersson, IF Petersson, KE Karlsson, EN Jonsson, B Månsson, ...
Annals of the rheumatic diseases 65 (11), 1490-1494, 2006
Advanced methods for dose and regimen finding during drug development: summary of the EMA/EFPIA workshop on dose finding (London 4–5 December 2014)
FT Musuamba, E Manolis, N Holford, SYA Cheung, LE Friberg, ...
CPT: pharmacometrics & systems pharmacology 6 (7), 418-429, 2017
Comparisons of analysis methods for proof‐of‐concept trials
KE Karlsson, C Vong, M Bergstrand, EN Jonsson, MO Karlsson
CPT: pharmacometrics & systems pharmacology 2 (1), 1-8, 2013
Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: Building model credibility
FT Musuamba, I Skottheim Rusten, R Lesage, G Russo, R Bursi, L Emili, ...
CPT: Pharmacometrics & Systems Pharmacology 10 (8), 804-825, 2021
Performance of three estimation methods in repeated time-to-event modeling
KE Karlsson, EL Plan, MO Karlsson
The AAPS journal 13, 83-91, 2011
Approaches to simultaneous analysis of frequency and severity of symptoms
EL Plan, KE Karlsson, MO Karlsson
Clinical Pharmacology & Therapeutics 88 (2), 255-259, 2010
Population pharmacokinetics of edoxaban in patients with non-valvular atrial fibrillation in the ENGAGE AF-TIMI 48 study, a phase III clinical trial
EHJ Krekels, R Niebecker, MO Karlsson, R Miller, T Shimizu, KE Karlsson, ...
Clinical Pharmacokinetics 55, 1079-1090, 2016
Randomized exposure‐controlled trials; impact of randomization and analysis strategies
KE Karlsson, A Grahnén, MO Karlsson, EN Jonsson
British journal of clinical pharmacology 64 (3), 266-277, 2007
Commentary on the EMA R eflection P aper on the use of extrapolation in the development of medicines for paediatrics
C Ollivier, A Thomson, E Manolis, K Blake, KE Karlsson, CAJ Knibbe, ...
British Journal of Clinical Pharmacology 85 (4), 659-668, 2019
Verifying and validating quantitative systems pharmacology and in silico models in drug development: current needs, gaps, and challenges
FT Musuamba, R Bursi, E Manolis, K Karlsson, A Kulesza, E Courcelles, ...
CPT: Pharmacometrics & Systems Pharmacology 9 (4), 195, 2020
Commentary on the MID3 good practices paper
E Manolis, J Brogren, S Cole, JL Hay, A Nordmark, KE Karlsson, F Lentz, ...
CPT: Pharmacometrics & Systems Pharmacology 6 (7), 416-417, 2017
Environmental risk assessment of sediments deposited in stormwater treatment facilities: trace metal fractionation and its implication for sediment management
K Karlsson, GT Blecken, B Öhlander, M Viklander
Journal of Environmental Engineering 142 (11), 04016057, 2016
Edoxaban Exposure‐Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep‐Vein Thrombosis or Pulmonary Embolism
J Nyberg, KE Karlsson, S Jönsson, OQP Yin, R Miller, MO Karlsson, ...
CPT: Pharmacometrics & Systems Pharmacology 5 (4), 222-232, 2016
Modeling disease progression in acute stroke using clinical assessment scales
KE Karlsson, JJ Wilkins, F Jonsson, PH Zingmark, MO Karlsson, ...
The AAPS journal 12, 683-691, 2010
Simulating large time-to-event trials in NONMEM
J Nyberg, KE Karlsson, S Jönsson, USH Simonsson, MO Karlsson, ...
Page 23, 3166, 2014
Benefits of pharmacometric model-based design and analysis of clinical trials
KE Karlsson
Acta Universitatis Upsaliensis, 2010
Fältarbetsinstruktion för Skogsfakultetens beståndsbehandlingsförsök
K Karlsson
Swedish University of Agricultural Sciences, 2003
The European medicines agency experience with pediatric dose selection
E Manolis, FT Musuamba, KE Karlsson
The Journal of Clinical Pharmacology 61, S22-S27, 2021
Motivation in the Gig Economy: A Case Study of Gig Workers in the IT and Business Consulting Industry
K Karlsson, J Wranne
A future legal coordinated cadastre for Sweden
K Karlsson
International Symposium and Exhibition on Geoinformation, 2005
The system can't perform the operation now. Try again later.
Articles 1–20